Cochrane · systematic review · CD003462
Heparin versus placebo for non‐ST elevation acute coronary syndromes
Andrade-Castellanos, CA, Colunga-Lozano, LE, Delgado-Figueroa, N, et al. · Cochrane Database of Systematic Reviews · 2014 · Cochrane Library
HeartAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
5
current version
GRADE rated
5
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 1 · 20%Low 4 · 80%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Heparin versus placebo for non‐ST elevation acute coronary syndromes
Population: patients with non‐ST elevation acute coronary syndromes
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All‐cause mortality Heparin vs placebo | RR 0.84 [0.36, 1.98] | 6 studies · 2426 participants | Low Downgraded: risk of bias, imprecision, publication bias |
Incidence of myocardial infarction Heparin vs placebo | RR 0.4 [0.25, 0.63] | 6 studies · 2426 participants | Low Downgraded: risk of bias |
Recurrent angina Heparin vs placebo | RR 0.81 [0.6, 1.09] | 6 studies · 2426 participants | Very low Downgraded: risk of bias |
Incidence of revascularization procedures Heparin vs placebo | RR 0.93 [0.76, 1.15] | 6 studies · 2520 participants | Low Downgraded: risk of bias |
Major hemorrhage Heparin vs placebo | RR 2.05 [0.91, 4.6] | 8 studies · 3118 participants | Low Downgraded: risk of bias |